LeadershipAdvocacy & Gov't AffairsHistoryCareers at Joslin
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Adult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingCommercialization and VenturesHealthcare Professionals
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

TrialNet

TrialNet is an international network of researchers dedicated to the study, prevention and early treatment of type 1 diabetes.

TrialNet conducts studies to:

  • Learn more about the factors that put some people at risk for developing diabetes,
  • Test treatments that could help delay or prevent diabetes, and
  • Test treatment that might help people keep producing their own insulin when they are first diagnosed with diabetes.

TrialNet is supported by the Department of Health and Human Services National Institutes of Health, Juvenile Diabetes Research Foundation International, and the American Diabetes Association.

TrialNet at Joslin Diabetes Center is an affiliate site of the Pathway to Prevention Study and several other TrialNet studies. The Pathway to Prevention Study (also known as the Natural History Study) screens relatives of people with type 1 diabetes to find out if family members are at risk for developing diabetes.

Type 1 diabetes is an autoimmune disease in which the immune system attacks and destroys the cells in the body that produce insulin. Proteins called autoantibodies are markers of the destruction. TrialNet offers a screening test that can detect these autoantibodies in the blood up to 10 years before someone is diagnosed with type 1 diabetes.

How can I participate in the Pathway to Prevention Study?

Inclusion Criteria

You may be able to take part in the Pathway to Prevention Study if you are:

  • Between the ages of 1 and 45 years old and have a brother, sister, child or parent who has been diagnosed with type 1 diabetes

-or-

  • Between 1 and 20 years old and have a cousin, niece, nephew, aunt, uncle, half sibling, or grandparent who had been diagnosed with type 1 diabetes.

Exclusion Criteria

You may not be able to participate if you:

  • Have diabetes already
  • Have a previous history of being treated with insulin or oral diabetes medications
  • Currently use systemic immunosuppressive agents (topical or inhaled agents are acceptable)
  • Have any known serious disease

Participation Involves

  • Blood draw of a single tube for diabetes related autoantibodies
  • Answering a few medical and family history questions
  • Results are typically available in about 4-6 weeks
  • Possible follow-up: individuals with a positive antibody result may be offered further testing to determine their risk of developing diabetes over the next 5 years. You would need to give additional permission to participate in the next stage of testing. Depending on the results of the testing, you may also be eligible to participate in other TrialNet studies.

For more information or to get screened contact the Joslin TrialNet team at TrialNet@joslin.harvard.edu or (617)309-4493.

For more information or to get screened contact the Joslin TrialNet team at TrialNet@joslin.harvard.edu
or (617)309-4493.

Page last updated: April 25, 2014